With Starboard Value lurking around acquirer Bristol-Myers Squibb (BMY), Celgene (CELG) shareholders are left with a minor risk that the deal gets blocked. The good news is that the company doesn't need Bristol-Myers. The bad news is that the initial reaction to a blocked deal is the stock falling to the $70s from a current price of $88.
Image Source: Starboard Value website
Starboard Lurking
According to Bloomberg reports, the hedge fund was looking at taking an activist position in Bristol-Myers insinuating that Starboard Value might want to block the